Günter Carl Hober
Managing Partner
+49 (89) 809 53 63- 0
Curriculum vitae & references Quickcontact
ConAlliance is specialised in conducting divestiture and acquisition activity within the pharmaceutical and biotechnology industry.
While representing the buy-side, we help pharmaceutical executives on the hunt for new therapies and new customers to drive growth. M&A deals for example, allow companies diversify product portfolios, secure pipeines of high-quality active pharmaceutical ingredients (API) and generic pharmaceuticals expand into emerging markets, and achieve economies of scale.
When we are engaged by the sell-side, we need to analyze the company, its strengths and weaknesses, the market and competitors, and much more. What is the best time for divestiture with reference to the life-cycle of the pharmaceutical product? Who are the potential buyers? What is the worth of the company and how can sales-revenue be maximized? How can the transaction be secured in terms of liabilities, guarantees and warranties?
Overall Mergers and Acquisitions can provide excellent possibilities to gain access to new products and markets, new revenue streams and geographic expansion to drive organic growth. Thus we are bringing two sides together: buyers and sellers of a pharmaceutical company.
At the same time we carry out on ongoing analysis of private European specialty life science companies, in order to advance M&A advisory services for our clients.
ConAlliance offers a holistic advisory service for the pharmaceutical and biotechnologic industry.
Our principles apply to all M&A mandates: We work with the utmost discretion, we are independent of banks and corporate groups and we exclusively represent the interests of our clients. Please contact us if you are interested in our M&A advisory services.
ConAlliance is the expert in healthcare investment banking in Europe.
Conalliance is the financial adviser of choice to health care and life science companies and institutional investors of all sizes, individuals and family firms throughout Europe.
This page provides benchmarks by considering acquisitions and divestitures in the pharmaceuticals, biotech and life science industry.
mergers acquisitions medical devices
|
mergers & acquisitions healthcare |
ConAlliance is the leading M&A Advisory Firm, when you are planning to sell medical device company |
Pharmaceutical and biotech companies are turning to mergers and acquisitions as a way to bolster their pipelines and improve efficiencies. As for future M&A activity, likely scenarios include additional mega deals, acquisition of generic firms, and mergers and acquisitions of biotech and other niche players to bolster dwindling pipelines. |
ConAlliance is expert in divestiture medical device company, acquire healthcare company, acquire healthcare business |
M&A advisory Pharmaceuticals M&A drugs Mergers & Acquisitions
Expertise and Experience in Mergers and Acquisitions to the life science industry.
M&A drugs Mergers & Acquisitions
|